Cargando…

Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma

Cells respond to various environmental factors such as nutrients, food intake, and drugs or toxins by undergoing dynamic epigenetic changes. An imbalance in dynamic epigenetic changes is one of the major causes of disease, oncogenic activities, and immunosuppressive effects. The aryl hydrocarbon rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Kwei-Yan, Wang, Li-Ting, Hsu, Shih-Hsien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789358/
https://www.ncbi.nlm.nih.gov/pubmed/29301348
http://dx.doi.org/10.3390/cancers10010008
_version_ 1783296259144024064
author Liu, Kwei-Yan
Wang, Li-Ting
Hsu, Shih-Hsien
author_facet Liu, Kwei-Yan
Wang, Li-Ting
Hsu, Shih-Hsien
author_sort Liu, Kwei-Yan
collection PubMed
description Cells respond to various environmental factors such as nutrients, food intake, and drugs or toxins by undergoing dynamic epigenetic changes. An imbalance in dynamic epigenetic changes is one of the major causes of disease, oncogenic activities, and immunosuppressive effects. The aryl hydrocarbon receptor (AHR) is a unique cellular chemical sensor present in most organs, and its dysregulation has been demonstrated in multiple stages of tumor progression in humans and experimental models; however, the effects of the pathogenic mechanisms of AHR on epigenetic regulation remain unclear. Apart from proto-oncogene activation, epigenetic repressions of tumor suppressor genes are involved in tumor initiation, procession, and metastasis. Reverse epigenetic repression of the tumor suppressor genes by epigenetic enzyme activity inhibition and epigenetic enzyme level manipulation is a potential path for tumor therapy. Current evidence and our recent work on deacetylation of histones on tumor-suppressive genes suggest that histone deacetylase (HDAC) is involved in tumor formation and progression, and treating hepatocellular carcinoma with HDAC inhibitors can, at least partially, repress tumor proliferation and transformation by recusing the expression of tumor-suppressive genes such as TP53 and RB1.
format Online
Article
Text
id pubmed-5789358
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-57893582018-02-02 Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma Liu, Kwei-Yan Wang, Li-Ting Hsu, Shih-Hsien Cancers (Basel) Review Cells respond to various environmental factors such as nutrients, food intake, and drugs or toxins by undergoing dynamic epigenetic changes. An imbalance in dynamic epigenetic changes is one of the major causes of disease, oncogenic activities, and immunosuppressive effects. The aryl hydrocarbon receptor (AHR) is a unique cellular chemical sensor present in most organs, and its dysregulation has been demonstrated in multiple stages of tumor progression in humans and experimental models; however, the effects of the pathogenic mechanisms of AHR on epigenetic regulation remain unclear. Apart from proto-oncogene activation, epigenetic repressions of tumor suppressor genes are involved in tumor initiation, procession, and metastasis. Reverse epigenetic repression of the tumor suppressor genes by epigenetic enzyme activity inhibition and epigenetic enzyme level manipulation is a potential path for tumor therapy. Current evidence and our recent work on deacetylation of histones on tumor-suppressive genes suggest that histone deacetylase (HDAC) is involved in tumor formation and progression, and treating hepatocellular carcinoma with HDAC inhibitors can, at least partially, repress tumor proliferation and transformation by recusing the expression of tumor-suppressive genes such as TP53 and RB1. MDPI 2018-01-03 /pmc/articles/PMC5789358/ /pubmed/29301348 http://dx.doi.org/10.3390/cancers10010008 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Liu, Kwei-Yan
Wang, Li-Ting
Hsu, Shih-Hsien
Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma
title Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma
title_full Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma
title_fullStr Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma
title_full_unstemmed Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma
title_short Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma
title_sort modification of epigenetic histone acetylation in hepatocellular carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789358/
https://www.ncbi.nlm.nih.gov/pubmed/29301348
http://dx.doi.org/10.3390/cancers10010008
work_keys_str_mv AT liukweiyan modificationofepigenetichistoneacetylationinhepatocellularcarcinoma
AT wangliting modificationofepigenetichistoneacetylationinhepatocellularcarcinoma
AT hsushihhsien modificationofepigenetichistoneacetylationinhepatocellularcarcinoma